MA54907A - Inhibiteurs de phosphoinositide 3-kinase topiques - Google Patents

Inhibiteurs de phosphoinositide 3-kinase topiques

Info

Publication number
MA54907A
MA54907A MA054907A MA54907A MA54907A MA 54907 A MA54907 A MA 54907A MA 054907 A MA054907 A MA 054907A MA 54907 A MA54907 A MA 54907A MA 54907 A MA54907 A MA 54907A
Authority
MA
Morocco
Prior art keywords
phosphoinonositide
topical
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
MA054907A
Other languages
English (en)
French (fr)
Inventor
Ahmed F Abdel-Magid
Agis Kydonieus
Thomas Rossi
Hock S Tan
Original Assignee
Venthera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Venthera Inc filed Critical Venthera Inc
Publication of MA54907A publication Critical patent/MA54907A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA054907A 2019-02-06 2020-02-05 Inhibiteurs de phosphoinositide 3-kinase topiques MA54907A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962802093P 2019-02-06 2019-02-06
US202062958049P 2020-01-07 2020-01-07

Publications (1)

Publication Number Publication Date
MA54907A true MA54907A (fr) 2022-05-11

Family

ID=71835949

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054907A MA54907A (fr) 2019-02-06 2020-02-05 Inhibiteurs de phosphoinositide 3-kinase topiques

Country Status (14)

Country Link
US (2) US11661429B2 (cg-RX-API-DMAC7.html)
EP (1) EP3920911A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022519317A (cg-RX-API-DMAC7.html)
KR (1) KR20210124310A (cg-RX-API-DMAC7.html)
CN (1) CN114072144A (cg-RX-API-DMAC7.html)
AU (1) AU2020219065A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021015353A2 (cg-RX-API-DMAC7.html)
IL (1) IL285020B2 (cg-RX-API-DMAC7.html)
MA (1) MA54907A (cg-RX-API-DMAC7.html)
MX (1) MX2021009142A (cg-RX-API-DMAC7.html)
SA (2) SA521422728B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202108274SA (cg-RX-API-DMAC7.html)
TW (1) TWI862548B (cg-RX-API-DMAC7.html)
WO (1) WO2020163525A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108274SA (en) 2019-02-06 2021-08-30 Venthera Inc Topical phosphoinositide 3-kinase inhibitors
EP4192431A1 (en) * 2020-08-04 2023-06-14 Venthera, Inc. Formulations of phosphoinositide 3-kinase inhibitors
EP4401732A4 (en) * 2021-09-15 2025-09-24 Dermbiont Inc COMPOSITIONS AND FORMULATIONS FOR TOPICAL USE OF AN AKT INHIBITOR FOR THE PREVENTION, TREATMENT, AND AMELIORATION OF SKIN DISEASES, CONDITIONS, AND DISORDERS
CN115991716B (zh) * 2021-10-19 2025-10-17 中国药科大学 嘧啶并环类化合物及其衍生物、制备方法、药物组合物和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5261001A (en) * 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
JP3602519B2 (ja) 2002-07-12 2004-12-15 コナミ株式会社 ビデオゲーム装置、画像処理方法及びプログラム
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
WO2007021933A2 (en) 2005-08-12 2007-02-22 The General Hospital Corporation Methods and compositions for use in treating vascular diseases and conditions
US8129371B2 (en) * 2007-10-16 2012-03-06 Wyeth Llc Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors
AU2008335156A1 (en) * 2007-12-10 2009-06-18 Metaproteomics, Llc Substituted 1,3-cyclopentadione multi-target protein kinase modulators of cancer, angiogenesis and the inflammatory pathways associated therewith
AU2008363813A1 (en) * 2008-11-07 2010-05-14 Children's Hospital Medical Center Fusogenic properties of saposin C and related proteins and peptides for application to transmembrane drug delivery systems
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
PT2385832E (pt) 2009-01-08 2015-11-02 Curis Inc Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco
EP2510121A1 (en) 2009-12-11 2012-10-17 Wyeth LLC Phosphatidylinositol-3-kinase pathway biomarkers
CN102268014B (zh) 2010-06-03 2015-06-03 上海艾力斯医药科技有限公司 一类稠合杂芳基衍生物、制备方法及其应用
GB201011771D0 (en) 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof
BR112013008615B1 (pt) 2010-10-13 2021-05-11 Medivir Ab composição farmacêutica
CN104010494B (zh) 2011-07-28 2017-07-04 霍夫曼-拉罗奇有限公司 Pik3ca h1047r敲入非人动物乳腺癌模型
US8871781B2 (en) 2011-11-30 2014-10-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating a subject for a lymphatic malformation
CN104379163A (zh) 2012-06-08 2015-02-25 霍夫曼-拉罗奇有限公司 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合
WO2014046617A1 (en) 2012-09-19 2014-03-27 Agency For Science, Technology And Research Compositions and methods for treating cancer
EP3294314A4 (en) 2015-05-15 2019-01-16 Memorial Sloan Kettering Cancer Center USE OF PHOPHOINOSITIDE-3-KINASE INHIBITORS FOR THE TREATMENT OF VASCULAR DISEASES
JP7051693B2 (ja) 2016-02-19 2022-04-11 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル PIK3CA関連過成長症候群(PROS CLOVaS症候群)の処置に使用するためのBYL719(アルペリシブ)
EP3251657A1 (en) 2016-05-30 2017-12-06 Sun Pharmaceutical Industries Limited Topical aqueous spray compositions of halobetasol
ES2893527T3 (es) 2016-12-28 2022-02-09 Hisamitsu Pharmaceutical Co Parche
SG11202108274SA (en) 2019-02-06 2021-08-30 Venthera Inc Topical phosphoinositide 3-kinase inhibitors
EP4192431A1 (en) 2020-08-04 2023-06-14 Venthera, Inc. Formulations of phosphoinositide 3-kinase inhibitors

Also Published As

Publication number Publication date
SA521422728B1 (ar) 2023-12-26
CN114072144A (zh) 2022-02-18
US12522614B2 (en) 2026-01-13
EP3920911A4 (en) 2023-03-08
AU2020219065A1 (en) 2021-09-23
MX2021009142A (es) 2021-10-13
JP2025036464A (ja) 2025-03-14
TWI862548B (zh) 2024-11-21
JP2022519317A (ja) 2022-03-22
KR20210124310A (ko) 2021-10-14
US20230416269A1 (en) 2023-12-28
JP7781250B2 (ja) 2025-12-05
EP3920911A1 (en) 2021-12-15
TW202045513A (zh) 2020-12-16
CA3127686A1 (en) 2020-08-13
SA522441650B1 (ar) 2024-02-29
IL285020B2 (en) 2025-11-01
US11661429B2 (en) 2023-05-30
WO2020163525A1 (en) 2020-08-13
US20200247816A1 (en) 2020-08-06
IL285020B1 (en) 2025-07-01
BR112021015353A2 (pt) 2021-10-05
SG11202108274SA (en) 2021-08-30
IL285020A (en) 2021-09-30

Similar Documents

Publication Publication Date Title
EP4007752C0 (en) Kif18a inhibitors
IL292643A (en) Ras inhibitors
IL292644A (en) Ras inhibitors
IL292642A (en) Ras inhibitors
EP4007753C0 (en) Kif18a inhibitors
EP4262803A4 (en) Tetrahydropyridopyrimidine pan-kras inhibitors
IL283639A (en) Kif18a inhibitors
EP4007756C0 (en) KIF18A INHIBITORS
EP3843714C0 (en) CD73 INHIBITORS
MA54550A (fr) Inhibiteurs de kif18a
MA52413A (fr) Inhibiteurs de cd73
IL290561A (en) Alkynyl quinazoline compounds
EP3801503A4 (en) INHIBITORS OF SARM1
PL4051688T3 (pl) Inhibitory cd73
EP3787635A4 (en) CD73 INHIBITORS
MA52813A (fr) Inhibiteurs de sarm1
EP3999517A4 (en) CD73 INHIBITORS
EP3980011C0 (en) SARM1 HIBITORS
EP3952870A4 (en) Phosphatidylinositol 3-kinase inhibitors
MA52809A (fr) Inhibiteurs de sarm1
IL285020A (en) Topical phosphoinositide 3-kinase inhibitors
EP3817736A4 (en) PIKFYVE INHIBITORS
HUE057970T2 (hu) Aminopirazindiol-vegyületek mint PI3K-Y inhibitorok
EP4003986A4 (en) Inhibitor compounds
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors